MicroRNA sequencing in patients with coronary artery disease - considerations for use as biomarker for thrombotic...

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Medicine

Background:

• MicroRNAs (miRNAs) are key regulators of gene expression.
• Circulating miRNAs are being investigated as potential biomarkers for cardiovascular diseases.
• Identifying patients with coronary artery disease (CAD) at risk for recurrent myocardial infarction (MI) after percutaneous coronary interventions (PCIs) is crucial for secondary prevention.

Purpose of the Study:

• To investigate the potential of circulating miRNA levels in whole blood and plasma to identify patients with CAD at risk for recurrent MI after PCI.
• To compare the utility of whole blood versus plasma samples for miRNA profiling in this patient population.

Main Methods:

• Subjects with CAD were selected from the GENCATH cardiac catheterization biobank.
• Next-generation miRNA sequencing was performed on plasma and whole blood samples.
• Patients with recurrent MI post-PCI were compared to those without recurrent MI in initial and replication cohorts.

Main Results:

• 164 miRNAs from whole blood were differentially expressed in the replication cohort (p < 0.05), with 69 significant after FDR correction.
• No significant differences in plasma miRNAs were observed between groups after FDR correction.
• Correlation between plasma and whole blood miRNA assays was variable; only two miRNAs were concordant and significant in both.

Conclusions:

• MiRNA profiling, particularly using whole blood, shows promise as a future biomarker for disease prognosis and treatment response in secondary prevention for CAD patients post-PCI.
• Whole blood appears to be a more suitable sample source than plasma for identifying risk of recurrent MI.